Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation
Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on the development of next-generation therapies targeting immunoglobulin E (IgE)-driven diseases. The proposed transaction marks a significant expansion of Novartis’ immunology and allergy portfolio, reinforcing its long-standing commitment to advancing innovative treatments for patients suffering from a wide range of allergic conditions.
At the center of the acquisition is Exl-111, Excellergy’s lead investigational asset, which is currently in Phase 1 clinical development. Exl-111 is a half-life-extended, high-affinity anti-IgE monoclonal antibody designed to improve upon existing anti-IgE therapies. By incorporating novel design features aimed at enhancing both pharmacokinetics and biological activity, the therapy represents a next-generation approach to modulating IgE-mediated immune responses.
Strengthening a Legacy in Allergy and Immunology
For Novartis, the acquisition builds upon decades of expertise in IgE biology and allergic disease management. The company has been a prominent player in immunology, with a well-established portfolio addressing conditions such as asthma, urticaria, and other allergic disorders. By integrating Excellergy’s innovative platform into its pipeline, Novartis aims to further strengthen its leadership position and accelerate the development of transformative therapies.
IgE is widely recognized as a central driver of multiple allergic diseases. It plays a key role in initiating and sustaining the type I hypersensitivity response, which underlies conditions such as food allergies, allergic asthma, and chronic urticaria. Targeting IgE has therefore been a validated therapeutic strategy, with existing treatments demonstrating clinical benefits in reducing symptoms and improving quality of life.
However, despite these advances, there remains a significant unmet need for therapies that can deliver faster onset of action, deeper suppression of allergic pathways, and more durable disease control. Exl-111 has been specifically engineered to address these gaps, offering the potential to go beyond the capabilities of first-generation anti-IgE therapies.
A Next-Generation Mechanism of Action
Unlike conventional anti-IgE antibodies, which primarily neutralize circulating IgE, Exl-111 is designed with a differentiated mechanism that enables it to actively dissociate IgE already bound to its high-affinity receptor, Fc epsilon RI alpha (FcεRIα), on immune cells. This capability could allow for more rapid and profound downregulation of IgE signaling pathways.
By targeting receptor-bound IgE, Exl-111 may accelerate the reduction of surface receptor expression on mast cells and basophils—key effector cells in allergic reactions. This, in turn, could lead to faster symptom relief and more effective suppression of allergic inflammation.
In addition to its novel mechanism, Exl-111 incorporates half-life extension technology, which is intended to prolong its presence in the bloodstream. Early pharmacokinetic data from ongoing Phase 1 studies suggest sustained exposure, supporting the potential for less frequent dosing and improved patient convenience.
Preclinical studies have further reinforced the promise of this approach, demonstrating enhanced potency and durability compared to traditional anti-IgE therapies. While these findings will need to be confirmed in larger clinical trials, they provide a strong foundation for continued development.
Broad Potential Across Allergic Diseases
The therapeutic potential of Exl-111 extends across a wide spectrum of IgE-mediated conditions. These include:
- Food allergies, where rapid and sustained suppression of allergic responses could reduce the risk of severe reactions
- Chronic spontaneous urticaria and chronic inducible urticaria, which are characterized by persistent hives and itching
- Allergic asthma, a condition driven by airway inflammation and hypersensitivity
- Other IgE-mediated disorders that may benefit from improved immune modulation
Importantly, the differentiated profile of Exl-111 may also support its use in diverse patient populations, including pediatric patients, where treatment options are often limited.
If clinical data continue to validate its mechanism and efficacy, Exl-111 could represent a versatile and impactful addition to the therapeutic landscape, potentially enabling earlier intervention, better disease control, and improved quality of life for patients.
Strategic Vision and Leadership Perspective
Fiona Marshall, President of Biomedical Research at Novartis, emphasized the strategic importance of the acquisition and the scientific rationale behind it. She highlighted that Excellergy’s program builds upon well-established IgE biology while introducing meaningful innovations that could enhance treatment outcomes.
According to Marshall, Exl-111 has been designed to deliver faster and deeper suppression of IgE signaling compared to existing therapies. This could translate into more effective symptom control and potentially redefine expectations for patients living with allergic diseases.
She also noted that the acquisition aligns with Novartis’ broader strategy of investing in bold, science-driven innovation. By pursuing next-generation therapies that address unmet needs, the company aims to bring meaningful benefits to patients and continue advancing the standard of care.
Transaction Details and Financial Structure
Under the terms of the agreement, Novartis will pay up to $2 billion in total consideration to acquire Excellergy. This includes an upfront payment as well as additional milestone-based payments tied to the achievement of specific development and regulatory objectives.
The transaction reflects the significant potential value of Exl-111 and the broader platform being developed by Excellergy. It also underscores the competitive landscape in immunology and allergy, where companies are increasingly seeking differentiated assets with the potential to deliver superior outcomes.
The acquisition is expected to close in the second half of 2026, subject to customary closing conditions, including regulatory approvals. Once completed, Excellergy’s operations and pipeline will be integrated into Novartis’ research and development framework.
The proposed acquisition represents a forward-looking investment in the future of allergy and immunology treatment. As scientific understanding of IgE biology continues to evolve, therapies like Exl-111 have the potential to unlock new possibilities for managing complex and chronic allergic conditions.
For Novartis, the addition of Excellergy’s technology and expertise is expected to enhance its ability to deliver innovative, patient-centered solutions. By combining established knowledge with cutting-edge science, the company is positioning itself to address some of the most pressing challenges in allergic disease management.
Ultimately, the success of this initiative will depend on the outcomes of ongoing and future clinical studies. However, the early data and scientific rationale supporting Exl-111 suggest that it could play a pivotal role in shaping the next generation of anti-IgE therapies.
As the transaction progresses toward completion, the industry will be watching closely to see how this collaboration translates into clinical advancements and, ultimately, improved outcomes for patients living with IgE-driven diseases.
About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.
Source Link:https://www.novartis.com/
